Exercise Prescription Moves to the Center of Cardio-Oncology Recovery
Cardiovascular toxicity can derail cancer treatment tolerance long before survivorship begins. In this narrative review, cardio-oncology rehabilitation is framed as more than general fitness counseling: it is a structured, risk-adaptive care model built around exercise prescription, multimodal monitoring, and implementation pathways for adults living through active cancer therapy or recovery.
The clinical logic is straightforward. Many patients enter treatment with pre-existing cardiovascular disease, then face additional injury from cardiotoxic therapy, deconditioning, fatigue, anemia, autonomic strain, and musculoskeletal loss. Under those conditions, exercise is not a wellness add-on; it becomes a therapeutic tool that may preserve functional capacity while treatment continues. The review draws on PubMed/MEDLINE and Web of Science Core Collection searches through 27 July 2026, prioritizing guidelines, systematic reviews, randomized and non-randomized studies, feasibility work, and selected mechanistic sources across three domains: exercise prescription, multimodal monitoring, and implementation.
Evidence across clinical trials supports gains in cardiorespiratory fitness, selected cardiovascular risk factors, and functional outcomes in some settings. Those effects are clinically meaningful because functional decline often determines whether a patient can stay on schedule with systemic therapy, tolerate surgery, or return to baseline activity after treatment. Even modest improvements in aerobic reserve can change day-to-day performance status, and in oncology that can translate into fewer treatment interruptions and more stable recovery trajectories. Yet the review is equally direct about the gaps: effects on cancer therapy-related cardiac dysfunction, cardiovascular events, and mortality remain uncertain.
A single sentence captures the tension in the field. The functional signal is real; the hard outcome signal is still missing.
Breast Cancer Dominates the Evidence, But the Clinical Problem Is Broader
The direct evidence base remains dominated by breast-cancer cohorts and women. That concentration reflects where rehabilitation studies have been most actively pursued, but it also limits confidence in how broadly the findings can be extended across oncology. Mixed-cancer populations, lymphoma studies, and lung-cancer cohorts expand the functional literature, yet they do not erase the fact that much of the practical evidence still comes from a relatively narrow set of patients and treatment contexts.
This matters because the physiologic burden of treatment differs across malignancies. Anthracycline exposure, chest radiation, HER2-targeted therapy, endocrine treatment, immune checkpoint inhibitors, and transplant-related exposures do not produce identical cardiovascular risk patterns. A rehabilitation program that works well for one group may need different intensity thresholds, surveillance intervals, or symptom triggers in another. The review therefore argues for individualized aerobic and resistance exercise tied to treatment context, symptoms, functional capacity, and clinical stability.
That approach fits bedside reality. A patient with stable exertional tolerance, no active decompensation, and preserved musculoskeletal capacity can often progress differently from a patient with ongoing dyspnea, orthostasis, peripheral neuropathy, or fluctuating hematologic status. Exercise dose in this setting is not a fixed prescription; it is a moving target adjusted to risk and tolerance.
Monitoring Has to Track What Exercise Alone Cannot See
The rehabilitation model in this review places multimodal monitoring alongside exercise prescription, not beneath it. In cardio-oncology, symptoms can be nonspecific and routine functional measures may miss evolving toxicity until reserve is already impaired. Monitoring is therefore positioned as the mechanism that links exercise with safety, timing, and escalation.
The authors propose reassessment linked to actionable findings rather than routine surveillance in the abstract. Clinically, that means monitoring should inform whether exercise continues, pauses, or shifts intensity, and whether a patient needs cardiac evaluation before further progression. This is particularly relevant when therapy-related cardiac dysfunction is a concern, because waiting for obvious symptomatic decline can mean intervening late. Exercise-induced hemodynamic stress, if paired with careful surveillance, may reveal limited reserve earlier than daily activity does.
The review also notes that artificial intelligence, digital twins, omics, and monitoring-guided exercise-dose adjustment remain investigational. Those tools are attractive because cardio-oncology is inherently dynamic: risk changes with cumulative exposure, regimen changes, symptom evolution, and recovery. Still, the current evidence does not support treating these technologies as routine clinical infrastructure. They remain concepts in search of validation.
Implementation Still Defines Whether Rehab Reaches the Bedside
Even a strong rehabilitation concept can fail if delivery is fragmented. The review treats implementation as a separate problem from efficacy, and that separation is clinically important. Patients with cancer already navigate multiple teams, competing priorities, transportation barriers, symptom burden, and fluctuating treatment schedules. A rehabilitation pathway that ignores those realities may never reach the people who could benefit most.
The proposed framework is described as conceptual and non-validated. That is a careful and necessary limitation. Risk-adaptive cardio-oncology rehabilitation sounds intuitive, but an intuitive pathway is not yet the same as a tested one. The next step is not simply broader enthusiasm; it is prospective evaluation of therapy-specific timing, risk-stratified delivery, monitoring-guided dose adjustment, clinical endpoints, equity, and cost-effectiveness.
Equity belongs in that list for a reason. Access to supervised rehabilitation, wearable monitoring, and oncology-cardiology coordination is uneven, and the patients who are least able to absorb missed visits or added costs are often those with the greatest physiologic burden. Implementation research will need to determine whether a rehabilitation model can work outside tertiary centers and whether it can be delivered without widening care gaps.
The Review Points Toward a Practical but Unproven Care Model
CORE is best understood here as exercise-centered care linked to guideline-based risk assessment and clinically indicated reassessment. The review does not claim that rehabilitation prevents cardiac events or improves survival. It does show that functional gains are possible, and it argues that those gains should be integrated into a structured care pathway rather than left to ad hoc advice.
For clinicians, the most useful message is the narrowing of priorities. Exercise should be individualized. Monitoring should be linked to clinical action. Delivery should be built for real oncology workflows. Outcomes should move beyond fitness scores alone and test whether rehabilitation changes cardiac toxicity, treatment tolerance, and longer-term recovery.
The unanswered question is not whether exercise matters in cancer care. The unanswered question is which patients benefit most, at what dose, under what monitoring, and through what delivery system capable of producing durable cardiovascular and oncologic value.